Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Pembrolizumab

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Nannini S, et al. Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current Oncology 31: 1656-1666, No. 3, Mar 2024. Available from: URL: https://dx.doi.org/10.3390/curroncol31030126 Nannini S, et al. Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current Oncology 31: 1656-1666, No. 3, Mar 2024. Available from: URL: https://​dx.​doi.​org/​10.​3390/​curroncol3103012​6
Metadaten
Titel
Pembrolizumab
Lack of efficacy
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58850-7

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Dacarbazine